{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:48:15Z","timestamp":1760204895360},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijantimicag.2016.12.016","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T03:39:23Z","timestamp":1488339563000},"page":"416-421","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients"],"prefix":"10.1016","volume":"49","author":[{"given":"Kenneth V.I.","family":"Rolston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A.","family":"Shelburne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall A.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0010","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society if America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0025","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","article-title":"Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance","volume":"32","author":"Montassier","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2016.12.016_bib0030","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients","volume":"30","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1086\/518873","article-title":"Polymicrobial infection in patients with cancer: an underappreciated and underreported entity","volume":"45","author":"Rolston","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.diagmicrobio.2016.01.010","article-title":"Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative staphylococcus causing infection in US hospitals","volume":"85","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.diagmicrobio.2015.10.028","article-title":"Ceftaroline activity tested against viridans group streptococci from US hospitals","volume":"84","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0050","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009\u201313)","volume":"70","author":"Sader","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0055","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","article-title":"Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0060","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/AAC.01452-08","article-title":"In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including \u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2016.12.016_bib0065","first-page":"iv41","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2016.12.016_bib0070","first-page":"iv53","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2016.12.016_bib0075","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2016.12.016_bib0080","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0085","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0090","series-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"1999"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0100","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0105","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10\u2009\u00d7\u2009'20 progress\u2014development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-3-319-04220-6_13","article-title":"Infections associated with solid malignancies","volume":"161","author":"Sutton","year":"2014","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-014-0048-4","article-title":"Current microbiology of surgical site infections in patients with cancer: a retrospective review","volume":"3","author":"Rolston","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0120","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/cid\/ciw113","article-title":"Causative organisms and associated antimicrobial resistance in healthcare-associated, central line-associated bloodstream infections from oncology settings, 2009\u20132012","volume":"62","author":"See","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0125","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","article-title":"Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center","volume":"17","author":"Mahajan","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2015.01.015","article-title":"Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013","volume":"82","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkv311","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme","volume":"71","author":"Karlowsky","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0145","first-page":"3259","article-title":"Susceptibility testing challenges with ceftaroline, MRSA and a 1\u2009mg\/l breakpoint","volume":"70","author":"Livermore","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0150","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cncr.21144","article-title":"Bacterial infections in low-risk, febrile neutropenic patients","volume":"104","author":"Kamana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0155","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/j.1875-9114.2012.01162.x","article-title":"Antimicrobial stewardship in patients with cancer","volume":"32","author":"Tverdek","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jinf.2012.11.007","article-title":"Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000\u20132011","volume":"66","author":"Shelburne","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu260","article-title":"Development and validation of a clinical model to predict the presence of \u03b2-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients","volume":"59","author":"Shelburne","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/JCM.44.1.160-165.2006","article-title":"Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases","volume":"44","author":"Han","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0175","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijantimicag.2013.10.004","article-title":"Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008\u20132011)","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0180","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/AAC.02274-13","article-title":"Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium","volume":"58","author":"Sakoulas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.016_bib0185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/cid\/ciq113","article-title":"Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians","volume":"52","author":"Kelesidis","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T23:50:01Z","timestamp":1658706601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0924857917300626"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}